Federal Anti-Monopoly Service reported 252 essential drug cost reduction

Since the beginning of 2023, it has been possible to reduce prices for 252 drugs within the framework of 40 international nonproprietary name’s (INNs) , which are included in the list of vital and essential drugs. This was reported in the press service of the Federal Antimonopoly Service.

“This became possible thanks to the economic analysis carried out by the service of the maximum selling prices of manufacturers, taking into account prices in foreign countries,” the message clarified. In particular, work was carried out to bring prices into line with those established in reference countries.

In addition, the cost reduction was facilitated by the entry of new generics into the Russian market. The FAS is certain that reducing medicine prices will level the playing field for their distribution and enhance accessibility for consumers.

Source